Advertisement

Advertisement

HotelsFoodShoppingCoffeeGroceryGas

Lyell Immunopharma, Inc

+1 (650) 695-0677
Website

Advertisement

Advertisement

201 Haskins Way Ste 101
South San Francisco, CA 94080
+1 (650) 695-0677
https://lyell.com

Lyell Immunopharma, Inc is a biotechnology company based in South San Francisco, CA, specializing in the development of innovative immunotherapies for the treatment of cancer.

With a focus on advancing personalized cell-based therapies, Lyell Immunopharma, Inc is dedicated to harnessing the power of the immune system to combat cancer and improve patient outcomes.

Generated from their business information

Also at this address

Novome Biotechnologies

YRC Worldwide Inc

Yrc

Yrc Freight

Own this business?
Claim it
See a problem?

You might also like

Internal medicine practitioners, Psychiatrists and psychoanalysts

Loxo Oncology

Loxo Oncology, based in South San Francisco, CA, is a biopharmaceutical company focused on developing targeted cancer therapies. With a commitment to advancing precision medicine, Loxo Oncology strives to address unmet medical needs in the field of oncology through innovative research and development. Generated from their business information
Biological laboratory, Sizes, Nonresidential construction, nec, nec

VistaGen Therapeutics, Inc

VistaGen Therapeutics, Inc is a biopharmaceutical company based in South San Francisco, CA, specializing in the development of innovative therapies for mental health disorders. With a focus on utilizing cutting-edge technology and research, VistaGen Therapeutics, Inc aims to address unmet medical needs and improve the lives of patients through its novel drug candidates. Generated from their business information

UNITY Biotechnology, Inc

UNITY Biotechnology, Inc. is a cutting-edge biotechnology company based in South San Francisco, CA, dedicated to developing therapeutics that target age-related diseases. Their innovative approach focuses on selectively eliminating or modulating senescent cells, which may restore aging or damaged tissues to a healthier state. With a particular emphasis on vision loss and cognitive decline, UNITY aims to treat these diseases while reducing healthcare costs and alleviating the burden on individuals, families, and communities. At the forefront of their research is UBX1325, the first senolytic approach designed to target senescent cells in the diseased vasculature of the eye, specifically for diabetic macular edema (DME). By providing a viable alternative to current treatment modalities, UNITY Biotechnology aims to revolutionize ophthalmology and transform the lives of individuals suffering from DME, the leading cause of blindness in adults with diabetes.Generated from the website
United States›California›South San Francisco›Lyell Immunopharma, Inc

Partial Data by Infogroup (c) 2024. All rights reserved.

Advertisement

Advertisement

  • Get directions
  • MapQuest Travel
  • Route Planner
  • Print your map
  • Get help
  • Search the web
  • Send feedback
Learn more about our mobile apps.
  • Android app Google Play
  • Download on the App Store
  • Download on the Amazon Appstore
  • Enterprise solutions
  • Claim your business
  • Developer resources
  • Jobs
  • Advertise with us
  • Terms of use
  • Privacy policy
  • Data and licenses
  • About our ads
  • Do not sell